Recent Updates
Recently added Catalysts
MREO Negative Sentiment Score: 15/100

Mereo BioPharma Group plc Class Action: The Gross Law Firm Reminds Mereo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – MREO

Key Takeaway: Mereo BioPharma Group plc faces a class action lawsuit due to allegations of misleading investors regarding the outcomes of its Phase 3 ORBIT and COSMIC programs. Both studies reportedly failed to achieve their primary endpoints, which contributed to a substantial drop in the company's stock price. The class action allows shareholders who purchased stock during the specified period to seek recovery without needing to be a lead plaintiff. Investors are encouraged to register before the lead plaintiff deadline of April 6, 2026.

Market Sentiment Analysis

CONCERNS & RISKS

  • Mereo BioPharma's clinical trials (ORBIT and COSMIC) failed to meet their primary endpoints, leading to a significant decline in stock price.
  • The company's share price plummeted by more than 87.7% in a short period after the announcement of trial failures.
  • Allegations suggest that Mereo misled investors by providing positive statements while concealing adverse facts.

Full Press Release Details

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).
Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: June 5, 2023 to December 26, 2025
ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. On December 29, 2025, Mereo issued a press release announcing that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance. The press release indicated that neither study met its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively, despite improved bone mineral density. Following this news, the price of Mereo’s ADS declined dramatically. From a closing market price of $2.31 per share on December 26, 2025, Mereo’s ADS price fell to $0.29 per share on December 29, 2025, a decline of more than 87.7%.
DEADLINE: April 6, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/mereo-biopharma-group-plc-loss-submission-form-5/?id=183851&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of MREO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 6, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Mereo BioPharma shareholders?

The class period for Mereo BioPharma shareholders is from June 5, 2023, to December 26, 2025.

How significant was the decline in Mereo's ADS price?

Mereo’s ADS price fell over 87.7%, from $2.31 on December 26, 2025, to $0.29 on December 29, 2025.

What should shareholders do to participate in the class action?

Shareholders should register by April 6, 2026, to participate in the class action.

Is there a cost to participate in the class action?

There is no cost or obligation to shareholders who wish to participate in the case.

What outcomes does Gross Law Firm aim for?

Gross Law Firm aims to secure recovery for investors harmed by deceitful and misleading company practices.

Last updated: Feb 26, 2026